ZA9711435B - Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists - Google Patents

Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists

Info

Publication number
ZA9711435B
ZA9711435B ZA9711435A ZA9711435A ZA9711435B ZA 9711435 B ZA9711435 B ZA 9711435B ZA 9711435 A ZA9711435 A ZA 9711435A ZA 9711435 A ZA9711435 A ZA 9711435A ZA 9711435 B ZA9711435 B ZA 9711435B
Authority
ZA
South Africa
Prior art keywords
agonists
prevention
treatment
receptor subtype
subtype selective
Prior art date
Application number
ZA9711435A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Hua Zhu Ke
Bruce Allen Lefker
Robert Louis Rosati
David Duane Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA9711435B publication Critical patent/ZA9711435B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9711435A 1996-12-20 1997-12-19 Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists ZA9711435B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3356996P 1996-12-20 1996-12-20

Publications (1)

Publication Number Publication Date
ZA9711435B true ZA9711435B (en) 1999-06-21

Family

ID=21871174

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9711435A ZA9711435B (en) 1996-12-20 1997-12-19 Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists

Country Status (19)

Country Link
US (1) US6426359B1 (xx)
EP (1) EP0951282B1 (xx)
JP (2) JP2000507961A (xx)
KR (1) KR100359557B1 (xx)
AT (1) ATE390917T1 (xx)
AU (1) AU4881697A (xx)
CA (1) CA2275595C (xx)
CY (1) CY2610B2 (xx)
DE (1) DE69738613T2 (xx)
DK (1) DK0951282T3 (xx)
ES (1) ES2303341T3 (xx)
HU (1) HUP0001836A3 (xx)
IL (2) IL130333A0 (xx)
MY (1) MY132818A (xx)
NZ (1) NZ335770A (xx)
PT (1) PT951282E (xx)
TW (1) TW562677B (xx)
WO (1) WO1998027976A1 (xx)
ZA (1) ZA9711435B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
DE69738613T2 (de) 1996-12-20 2009-04-30 Pfizer Inc. Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
EP1000619A3 (en) * 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
AU9756898A (en) * 1998-11-12 2000-06-05 Gemini Genomics Ab Human prostaglandin receptors and methods of use thereof
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
EE200200355A (et) * 1999-12-22 2003-10-15 Pfizer Products Inc. EP4 retseptori selektiivsed agonistid osteoporoosi raviks
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
BR0214614A (pt) * 2001-11-30 2004-09-14 Pfizer Prod Inc Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2
WO2004073591A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
EP1601351A1 (en) * 2003-03-04 2005-12-07 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
WO2005009468A1 (ja) * 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
DK1846354T3 (da) 2005-01-14 2010-08-16 Allergan Inc Substituterede cyclopentaner eller cyclopentanoner til behandling af okular hypertensive tilstande
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7323591B2 (en) * 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
EP2220057A4 (en) * 2007-11-14 2011-10-12 Cayman Chem Co PROSTAGLANDIN E1 AND E2 ANALOGUES FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
EP2291346A2 (en) * 2008-05-15 2011-03-09 Allergan, Inc. Therapeutic substituted cyclopentanes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4112236A (en) 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
AU615534B2 (en) 1988-04-19 1991-10-03 Teijin Limited 2-substituted-2-cyclopentenones
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
DE69738613T2 (de) 1996-12-20 2009-04-30 Pfizer Inc. Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater

Also Published As

Publication number Publication date
ATE390917T1 (de) 2008-04-15
WO1998027976A1 (en) 1998-07-02
DE69738613T2 (de) 2009-04-30
AU4881697A (en) 1998-07-17
KR20000057680A (ko) 2000-09-25
KR100359557B1 (ko) 2002-11-08
IL130333A0 (en) 2000-06-01
CA2275595C (en) 2003-08-05
US6426359B1 (en) 2002-07-30
CA2275595A1 (en) 1998-07-02
PT951282E (pt) 2008-06-09
EP0951282B1 (en) 2008-04-02
EP0951282A1 (en) 1999-10-27
JP2000507961A (ja) 2000-06-27
CY2610B2 (en) 2010-10-22
HUP0001836A2 (hu) 2000-09-28
TW562677B (en) 2003-11-21
MY132818A (en) 2007-10-31
DK0951282T3 (da) 2008-07-14
JP2006290895A (ja) 2006-10-26
IL130333A (en) 2007-02-11
ES2303341T3 (es) 2008-08-01
HUP0001836A3 (en) 2001-05-28
DE69738613D1 (de) 2008-05-15
NZ335770A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
CY2610B2 (en) Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 a gonists
BG102690A (en) Il-8 receptor antagonists
BG102726A (en) Combined therapy for osteoporosis
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
DE69626660D1 (en) 2-alkylpyrrolidine
GB2333453A (en) Colostrinin and uses thereof
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
AU3508497A (en) Androgen receptor modulator compounds and methods
NO964966L (no) Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav
UA43378C2 (uk) Композиція для лікування респіраторного дистрес-синдрому новонароджених та респіраторного дистрес-синдрому дорослих
WO2000006085A3 (en) Compounds and methods
ID27820A (id) APLIKASI-APLIKASI PENGOBATAN POLIPEPTIDA MATURE FLINT (mFLINT) ATAU OPG3, BAGIAN KELOMPOK SUPER RESEPTOR TNF
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
BR9510499A (pt) Antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados po il-5
EP1632248B8 (en) Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
TR199900505T2 (xx)
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
DE3378979D1 (en) 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents
IL139303A0 (en) Treatment of arthritis and other similar conditions
AU5244998A (en) Morphogen-induced regeneration of sense perceptory tissues
EP0880971A3 (en) Macrophage stimulating protein for the treatment of pathologies of the nervous system